Development and validation of nomogram including high altitude as a risk factor for COPD: A cross-sectional study based on Gansu population.

Background: Chronic Obstructive Pulmonary Disease (COPD) is a common and harmful disease that requires an effective tool to early screen high-risk individuals. Gansu has unique environments and customs, leading to the different prevalence and etiology of COPD from other regions. The association between altitude and COPD once attracted epidemiologists' attention. However, the prevalence in Gansu and the role of altitude are still unclarified. Methods: In Gansu, a multistage stratified cluster sampling procedure was utilized to select a representative sample aged 40 years or older. The questionnaire and spirometry examination were implemented to collect participants' information. The diagnosis and assessment of COPD were identified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criterion, while post-bronchodilator FEV1/FVC < LLN was for sensitivity analysis. Furthermore, the effect of high altitude on COPD was evaluated by the logistic regression model after propensity score matching (PSM). Finally, the participants were randomly divided into training and validation sets. The training set was used to screen the relative factors and construct a nomogram which was further assessed by the receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA) in the two sets. Results: There were 2,486 eligible participants in the final analysis, of which 1,584 lived in low altitudes and 902 lived in high altitudes. Based on the GOLD criterion, the crude and standardized prevalences in Gansu were 20.4% (18.7-22.0) and 19.7% (17.9-21.6). After PSM, the logistic regression model indicated that high altitude increased COPD risk [PSM OR: 1.516 (1.162-1.978)]. Altitude, age, sex, history of tuberculosis, coal as fuel, and smoking status were reserved for developing a nomogram that demonstrated excellent discrimination, calibration, and clinical benefit in the two sets. Conclusions: COPD has become a serious public health problem in Gansu. High altitude is a risk factor for COPD. The nomogram has satisfactory efficiency in screening high-risk individuals.

Predictive value of LncRNA on coronary restenosis after percutaneous coronary intervention in patients with coronary heart disease: A protocol for systematic review and meta-analysis.

BACKGROUND: Evidence shows that long-stranded non-coding RNA (LncRNA) can predict coronary artery restenosis in patients suffering from coronary heart disease after percutaneous coronary intervention, suggesting that LncRNA may become a promising biomarker for the diagnosis of coronary artery restenosis after percutaneous coronary intervention. However, its accuracy has not been systematically evaluated. Therefore, it is necessary to perform meta-analysis to certify the diagnostic value of LncRNA on coronary artery restenosis after percutaneous coronary intervention. METHODS: PubMed, EMBASE, Cochrane Library, and Web of Science were searched for relevant studies to explore the potential diagnostic values of LncRNA on coronary artery restenosis after percutaneous coronary intervention from inception to December 2020. Data were extracted by two experienced researchers independently. The risk of bias about the meta-analysis was confirmed by the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2). Data was synthesized and heterogeneity was investigated as well. All of the above statistical analysis was carried out with Stata 14.0. RESULTS: This study proved the pooled diagnostic performance of LncRNA on coronary artery restenosis after percutaneous coronary intervention. CONCLUSION: This study clarified confusions about the specificity and sensitivity of LncRNA on coronary artery restenosis after percutaneous coronary intervention, thus further guiding their promotion and application. ETHICS AND DISSEMINATION: Ethical approval is not required for this study. The systematic review will be published in a peer-reviewed journal, presented at conferences, and shared on social media platforms. This review would be disseminated in a peer-reviewed journal or conference presentations. OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/4QT2P.

Associations Between Common Polymorphisms of CDKN2B-AS and Susceptibility to ASCVD.

This meta-analysis was conducted to estimate associations between CDKN2B antisense (CDKN2B-AS) polymorphisms and susceptibility to atherosclerotic cardio-cerebral vascular diseases (ASCVD). A systematic literature research of PubMed, Medline, Web of Science, Embase, and CNKI was performed to identify eligible studies. Overall, 34 studies were included for meta-analyses. Pooled overall analyses showed that rs1333040, rs1333049, rs2383206, and rs2383207 polymorphisms were associated with susceptibility to ASCVD in the whole population. Further analyses by ethnicity revealed that all investigated polymorphisms were associated with susceptibility to ASCVD in East Asians. Moreover, rs2383206, rs2383207, rs10757274, and rs10757278 polymorphisms were associated with susceptibility to ASCVD in West Asians, while rs2383206, rs10757274, and rs10757278 were associated with susceptibility to ASCVD in Caucasians. When we stratified eligible studies by type of disease, positive results were found for all investigated polymorphisms in patients with coronary artery disease (CAD) or myocardial infarction, whereas positive results were only detected for rs2383206 and rs10757274 polymorphisms in patients with ischemic stroke (IS). Our findings suggest that rs1333040, rs1333049, rs2383206, rs2383207, rs10757274, and rs10757278 polymorphisms might serve as genetic biomarkers of CAD, and rs2383206 and rs10757274 polymorphisms might serve as genetic biomarkers of IS.

Association between α-adducin rs4961 polymorphism and hypertension: A meta-analysis based on 40 432 subjects.

BACKGROUND: Recently, the role of α-adducin rs4961 polymorphism in hypertension (HTN) was intensively analyzed, but the results of these studies were inconsistent. Therefore, we performed this study to better assess the relationship between α-adducin rs4961 polymorphism and the likelihood of HTN. METHODS: Eligible studies were searched in PubMed, Medline, Embase, and Web of Science. Odds ratios with 95% confidence intervals were used to assess the relationship between α-adducin rs4961 polymorphism and HTN. RESULTS: A total of 33 studies with 40 432 participants were analyzed. Significant associations with the likelihood of HTN were detected for the α-adducin rs4961 polymorphism with fixed effect models (FEM) (dominant model: P = 0.003; allele model: P = 0.003), but not with random effect models (REM). Further subgroup analysis according to ethnicity of participants revealed that the α-adducin rs4961 polymorphism was significantly associated with the likelihood of HTN in Asians (7721 cases and 8299 controls) with both FEMs (dominant model: P < 0.0001; additive model: P = 0.01; allele model: P < 0.0001) and REMs (dominant model: P = 0.0005; additive model: P = 0.03; allele model: P = 0.0006). CONCLUSIONS: Our findings indicate that the α-adducin rs4961 polymorphism may serve as a genetic biomarker of HTN in Asians.

WITHDRAWN: A meta-analysis on associations of CDKN2B-AS variants with atherosclerotic cardio-cerebral vascular diseases.

This article has been withdrawn at the request of the editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal.

Changes in matrix metalloproteinase-9 levels during progression of atrial fibrillation.

OBJECTIVES: To observe levels of matrix metalloproteinase (MMP)-9 and evaluate their significance in various stages of idiopathic atrial fibrillation (AF). METHODS: Patients with idiopathic AF were recruited into this prospective study and classified into one of three groups according to stage of disease progression: paroxysmal AF; persistent AF; permanent AF. Healthy individuals were enrolled as control subjects. Serum levels of MMP-9 in all four groups were determined using a double-antibody sandwich enzyme-linked immunosorbent assay. RESULTS: Each AF group included 25 patients; 40 healthy individuals were included as controls. MMP-9 levels in the three AF groups were significantly higher than in the control group: 168.72 ± 25.970, 201.36 ± 31.26 and 253.20 ± 22.99 ng/ml for the paroxysmal, persistent and permanent AF groups respectively, versus 76.80 ± 14.90 ng/ml for the control group. MMP-9 levels increased with idiopathic AF disease progression (P < 0.05). CONCLUSIONS: An elevated MMP-9 level appears to be associated with a diagnosis of AF. MMP-9 levels appear to increase in relation to the stage of idiopathic AF progression.